tiprankstipranks
Trending News
More News >
Prostatype Genomics AB (SE:PROGEN)
:PROGEN

Prostatype Genomics AB (PROGEN) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Prostatype Genomics AB

(Frankfurt:PROGEN)

Rating:35Underperform
Price Target:
Prostatype Genomics AB's overall stock score is low, primarily due to significant financial challenges, including ongoing losses and negative cash flows, which raise concerns about the company's sustainability. The technical analysis indicates a bearish trend, with all indicators pointing to weakness. The negative P/E ratio and absence of dividends further contribute to the low valuation score. To improve, the company needs to address its revenue generation and operational efficiencies.

Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)

Prostatype Genomics AB Business Overview & Revenue Model

Company DescriptionProstatype Genomics AB (PROGEN) is a biotechnology company specializing in the development and commercialization of precision diagnostic tests for prostate cancer. The company's flagship product, Prostatype, is a gene expression test designed to assess the aggressiveness of prostate cancer, aiding clinicians in making more informed treatment decisions. Prostatype Genomics operates in the healthcare and life sciences sectors, focusing on improving patient outcomes through innovative genomic solutions.
How the Company Makes MoneyProstatype Genomics AB generates revenue primarily through the sale of its Prostatype test to healthcare providers and institutions. The company may partner with laboratories, hospitals, and clinics that administer the Prostatype test to patients, thus earning income from test sales and possible licensing agreements. Additionally, collaborations with research institutions and potential partnerships with pharmaceutical companies for joint research and development projects could provide supplementary revenue streams. The company's income is heavily reliant on the adoption and utilization of its testing solutions within the medical community, as well as its ability to expand into new markets and maintain regulatory approvals.

Prostatype Genomics AB Financial Statement Overview

Summary
Prostatype Genomics AB faces significant financial challenges with ongoing losses, inconsistent revenue growth, and reliance on external financing. While the balance sheet shows a strong equity position, the lack of profitability and negative cash flows indicate operational inefficiencies and potential sustainability risks.
Income Statement
20
Very Negative
Prostatype Genomics AB has consistently experienced negative net income and negative EBIT over the years, indicating ongoing operational losses. The gross profit margins are not sustainable as they are driven by minimal revenue and high costs. The revenue growth is highly inconsistent, with recent declines suggesting challenges in expanding its market presence.
Balance Sheet
45
Neutral
The company maintains a healthy equity ratio, suggesting a strong equity position relative to total assets. However, the absence of total debt in recent reports reflects a lack of leverage, which could indicate limited access to external financing or a conservative financial strategy. The return on equity is negative due to ongoing losses, highlighting inefficiencies in generating returns from shareholders' equity.
Cash Flow
30
Negative
Prostatype Genomics AB's cash flow situation is concerning, with consistent negative free cash flow, indicating that the company is not generating enough cash from operations to fund its capital expenditures. The high operating cash outflow compared to net income suggests operational inefficiencies. The company relies heavily on financing cash flow to meet its cash needs, which could pose sustainability risks.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
469.75K199.00K1.36M683.00K10.00K683.88K
Gross Profit
-13.55M1.92M3.73M683.00K2.51M-14.20M
EBIT
-25.77M-40.85M-39.25M-28.69M-15.55M-16.62M
EBITDA
-24.44M-37.40M-38.02M-26.79M-15.46M-15.76M
Net Income Common Stockholders
-26.23M-41.05M-41.44M-29.09M-15.63M-17.41M
Balance SheetCash, Cash Equivalents and Short-Term Investments
10.52M9.42M2.68M11.49M20.33M15.86M
Total Assets
28.67M41.97M49.22M30.95M40.20M33.66M
Total Debt
1.43M0.0011.67M867.00K1.27M1.47M
Net Debt
-9.09M-9.42M8.98M-3.94M-8.56M-14.40M
Total Liabilities
3.80M8.50M24.55M4.80M4.30M5.37M
Stockholders Equity
24.87M33.47M24.67M26.15M35.91M28.29M
Cash FlowFree Cash Flow
-27.44M-52.57M-37.70M-27.69M-18.58M-14.74M
Operating Cash Flow
-27.44M-44.71M-29.14M-27.69M-16.08M-14.71M
Investing Cash Flow
5.11K-8.36M-8.57M0.00-2.50M-3.26M
Financing Cash Flow
39.63M59.75M28.91M18.85M23.05M31.14M

Prostatype Genomics AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.22
Price Trends
50DMA
1.46
Negative
100DMA
2.58
Negative
200DMA
4.64
Negative
Market Momentum
MACD
-0.04
Negative
RSI
47.17
Neutral
STOCH
7.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.46, and below the 200-day MA of 4.64, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.17 is Neutral, neither overbought nor oversold. The STOCH value of 7.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
kr48.56M-236.60%132.67%58.89%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
42
Neutral
kr4.02M-44.57%-30.56%7.17%
35
Underperform
kr40.73M-139.61%-85.32%92.64%
34
Underperform
€29.19M-105.54%63.82%
34
Underperform
€69.48M
29
Underperform
kr55.64M
0.10%41.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:PROGEN
Prostatype Genomics AB
1.22
-10.75
-89.84%
SE:AINO
Aino Health AB
0.35
0.25
238.46%
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
1.90
0.02
0.80%
SE:PLUN
ProstaLund AB
1.06
-20.54
-95.09%
SE:STABL
Stayble Therapeutics AB
0.43
0.17
63.36%
SE:HEART
Scandinavian Real Heart AB
13.60
-25.60
-65.31%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.